Publications by authors named "N Vora"
Rho(D) immune globulin shortage and fetal Rh(D) screening with cell-free DNA.
Curr Opin Obstet Gynecol
December 2024
Purpose Of Review: Despite the availability of Rh(D) immune globulin (RhIg) to prevent alloimmunization in Rh(D)-negative pregnant patients, anti-Rh(D) alloimmunization remains a prevalent cause of hemolytic disease of the fetus and newborn (HDFN). Recent RhIg shortages have caused clinicians and professional societies to identify methods to prioritize RhIg administration. New cell-free DNA (cfDNA) tests to predict fetal red blood cell antigen genotypes have been proposed as an option to prioritize the administration of RhIg to Rh(D)-negative pregnant people.
View Article and Find Full Text PDFObjective: To report a case of a fetus with multiple congenital anomalies and suspected Barth syndrome, highlighting potential phenotypic expansion of the syndrome.
Methods: A 32-year-old G4P2011 patient was referred at 18w5d gestation for suspected fetal encephalocele. Serial imaging, including ultrasound and MRI, was performed to evaluate fetal anomalies.
Article Synopsis
- New medications called highly effective modulator therapy are improving health for many people with cystic fibrosis (CF), leading to more pregnancies among these individuals.
- The safety of these medications during pregnancy is unclear, as limited data show potential risks, such as health declines in patients when therapy is stopped and possible cataract development in offspring.
- Ongoing studies are expected to shed light on these safety concerns, highlighting the importance of thorough counseling for people with CF considering pregnancy.